Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease
Niketa C. Shah, Shalini Shenoy(Washington University in St. Louis), Geoff D.E. Cuvelier(CancerCare Manitoba), Andrew L. Gilman(Gene Therapy Laboratory), Kamar Godder(Miami Children's Hospital), Naynesh Kamani(American Association of Blood Banks), Michael Grimley(Cincinnati Children's Hospital Medical Center), Monica Bhatia(Columbia University Irving Medical Center), Allistair Abraham(Children's National), Lolie C. Yu(Louisiana State University), Martin Andreánsky(University of Miami Health System), David A. Jacobsohn(Children's National), Jodi Skiles(Indiana University School of Medicine), Sonali Chaudhury(Northwestern University), Alexander Ngwube(Children's Cancer Center), Sweta Bhoopatiraju(Children's Minnesota), Gregory A. Hale(Johns Hopkins University), Eric Anderson(University of California San Diego)
Cited by 5
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|442
Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel
|Haematologica|2014|389
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD
|Journal of Clinical Oncology|2021|255
Allogeneic Human Mesenchymal Stem Cell Therapy (Remestemcel-L, Prochymal) as a Rescue Agent for Severe Refractory Acute Graft-versus-Host Disease in Pediatric Patients
|Transplantation and Cellular Therapy|2013|248